TC BioPharm (Holdings) plc (TCBP)
| Market Cap | 26.80M |
| Revenue (ttm) | 2.73M |
| Net Income (ttm) | -5.17M |
| Shares Out | 28.06M |
| EPS (ttm) | -0.18 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 176,367 |
| Open | 0.990 |
| Previous Close | 0.953 |
| Day's Range | 0.901 - 1.040 |
| 52-Week Range | 0.880 - 3.500 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About TCBP
TCB is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled TCB to develop a range of clinical-stage cell therapies designed to combat identified cancers and viral infections. TCB is embarking on phase II-into-pivotal (phase III) clinical studies, which are expected to commence in the fourth quarter of 2021, following United Kingdom and European Union regulati...
Financial Performance
In 2020, TCBP's revenue was 1.98 million, a decrease of -42.26% compared to the previous year's 3.43 million. Losses were -5.46 million, -10.05% less than in 2019.
Financial numbers in millions GBPFinancial StatementsNews
TC BioPharm Invited to Present at LD Micro Conference
EDINBURGH, Scotland , May 3, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform a...
TC BioPharm to Participate in Upcoming Conferences
EDINBURGH, Scotland , April 26, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platfor...
TC BioPharm Donates to Leukemia and Lymphoma Society in Sponsorship of World AML Day
EDINBURGH, Scotland , April 21, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platfor...
TC BioPharm Receives CryoTC® Trademark for Proprietary Cell Freezing Process
6-month shelf-life milestone achieved Successful thaw of highly activated Gamma delta cells EDINBURGH, Scotland , April 6, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company"...
TC BioPharm Announces Initiation of Equity Analyst Coverage by EF Hutton with a "Buy" Recommendation
EDINBURGH, Scotland , March 29, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platfor...
TC BioPharm Receives MHRA and Research Ethics Committee Approvals to Initiate Phase 2B/3 Clinical Trials for the Trea...
Trial enrollment expected to begin during the first half of 2022 EDINBURGH, Scotland , March 23, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: ...
Why Are TC Biopharm Shares Trading Higher Today
The FDA has granted Orphan Drug designation to TC Biopharm Ltd's (NASDAQ: TCBP) lead product OmnImmune for use in Acute Myeloid Leukemia. After reviewing the Phase 1b/2a trial results in relapsed/refra...
TC BioPharm Announces FDA Orphan Drug Status Granted for OmnImmune®
Allogeneic unmodified Gamma Delta product can be stored frozen and used as an 'off-the-shelf' cell therapy EDINBURGH, Scotland , March 17, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" ...
TC Biopharm Updates Intellectual Property Portfolio
EDINBURGH, Scotland, March 15, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform...
Newly-Listed TC Biopharm Highlights Early Data From Acute Myeloid Leukemia Trial
TC Biopharm Ltd (NASDAQ: TCBP) has announced interim data from Phase 1a/2b of TCB-002, OmnImmune in relapsed/refractory Acute Myeloid Leukemia (AML). TCB-002 is the Company's allogeneic unmodified gamm...
TC BioPharm Announces Positive Phase 1b/2a Data in Late-Stage Acute Myeloid Leukemia Patients Treated with Allogeneic...
EDINBURGH, Scotland, March 8, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform ...
TC Biopharm to Host Corporate Update Call on March 8th
EDINBURGH, Scotland, March 2, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform ...
TC Biopharm Announces Appointment of New Board Members
EDINBURGH, Scotland, Feb. 22, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform ...
TC Biopharm Announces Closing of $17.5 Million Initial Public Offering
EDINBURGH, Scotland, Feb. 15, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform ...
Top Penny Stocks to Buy Right Now? 3 to Watch in Mid-February
Here's three penny stocks that investors are watching rig The post Top Penny Stocks to Buy Right Now? 3 to Watch in Mid-February appeared first on Penny Stocks to Buy, Picks, News and Information | Pe...
5 ‘Must Watch' Penny Stocks For February 2022
5 must watch penny stocks that you should know about in February The post 5 ‘Must Watch' Penny Stocks For February 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
TC BioPharm Begins Trading on Nasdaq Today Under Symbol "TCBP"
EDINBURGH, Scotland, Feb. 11, 2022 /PRNewswire/ -- TC BioPharm (Holdings) plc ("TC BioPharm"), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for canc...